Trial Profile
A Phase II Study of ZD1839 (Iressa) [gefitinib] in Chemotherapy Refractory Germ Cell Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Germ cell cancer
- Focus Therapeutic Use
- 13 Nov 2005 New trial record.